

PARAFON FORTE DSC - chlorzoxazone tablet
REMEDYREPACK INC.

DESCRIPTION

Each caplet (capsule shaped tablet) contains:

*

5-chlorobenzoxazolinone Chlorzoxazone*500 mg

Inactive ingredients: FD&C Blue No. 1, microcrystalline cellulose, docusate sodium, lactose (hydrous), magnesium stearate, sodium benzoate, sodium starch glycolate, pregelatinized corn starch, D&C Yellow No. 10.

ACTIONS

Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Blood levels of chlorzoxazone can be detected in people during the first 30 minutes and peak levels may be reached, in the majority of the subjects, in about 1 to 2 hours after oral administration of chlorzoxazone. Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide. Less than one percent of a dose of chlorzoxazone is excreted unchanged in the urine in 24 hours.

INDICATIONS

PARAFON FORTE DSC chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

PARAFON FORTE DSC chlorzoxazone is contraindicated in patients with known intolerance to the drug.

WARNINGS

Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g. AST, ALT, alkaline phosphatase and bilirubin).

The concomitant use of alcohol or other central nervous system depressants may have an additive effect.

Usage in Pregnancy

The safe use of PARAFON FORTE DSC chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of

childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.

PRECAUTIONS

PARAFON FORTE DSC chlorzoxazone should be used with caution in patients with known allergies or with a history of allergic reactions to drugs. If a sensitivity reaction occurs such as urticaria, redness, or itching of the skin, the drug should be stopped.

If any symptoms suggestive of liver dysfunction are observed, the drug should be discontinued.

ADVERSE REACTIONS

Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or overstimulation may be noted by an occasional patient. Rarely, allergic-type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.

DOSAGE & ADMINISTRATION

Usual Adult Dosage

One caplet three or four times daily. If adequate response is not obtained with this dose, it may be increased to 1 1/2 caplets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.

OVERDOSAGE

Symptoms

Initially, gastrointestinal disturbances such as nausea, vomiting, or diarrhea together with drowsiness, dizziness, lightheadedness or headache may occur. Early in the course there may be malaise or sluggishness followed by marked loss of muscle tone, making voluntary movement impossible. The deep tendon reflexes may be decreased or absent. The sensorium remains intact, and there is no peripheral loss of sensation. Respiratory depression may occur with rapid, irregular respiration and intercostal and substernal retraction. The blood pressure is lowered, but shock has not been observed.

Treatment

Gastric lavage or induction of emesis should be carried out, followed by administration of activated charcoal. Thereafter, treatment is entirely supportive. If respirations are depressed, oxygen and artificial respiration should be employed and a patent airway assured by use of an oropharyngeal airway or endotracheal tube. Hypotension may be counteracted by use of dextran, plasma, concentrated albumin or a vasopressor agent such as norepinephrine. Cholinergic drugs or analeptic drugs are of no value and should not be used.

HOW SUPPLIED

PARAFON FORTEDSC (chlorzoxazone) 500 mg caplets, (capsule shaped tablet, colored light green, imprinted "PARAFON FORTE DSC" and "McNEIL," scored).

NDC 50458-625-60, bottles of 100.

STORAGE AND HANDLING

Store at controlled room temperature (15-30 C, 59-86 F).

Dispense in tight container as defined in the official compendium.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION

DRUG: Parafon Forte DSC
GENERIC: chlorzoxazone
DOSAGE: TABLET
ADMINISTRATION: ORAL
NDC: 49349-766-20
STRENGTH:500 mg
COLOR: green
SHAPE: OVAL
SCORE: Two even pieces
SIZE: 17 mm
IMPRINT: 100
QTY: 100



**PARAFON FORTE DSC
CAPLET**

**500 MG
QTY:00100**

NDC#: 49349-0766-20 INT:MS ID#:MCNEIL

EXPIRES: 11/2013

LOT#: DP1112012345

COL: green

SHP:oval

DIST: JANSSEN PHARMA INC RARITAN NJ 08869

MFG: JANSSEN ORTHO LLC GURABO PR 00778

A. Caution Federal law prohibits transfer of this drug to any person other than for whom it was prescribed.

B. Store at a temperature between 15 degree C and 30 degree C (59 degree F and 86 degree F) {see USP}

C. Re-packaged by: RemedyRepack Inc. 655 Koiter Dr., Indiana, PA 16701, 1-724-465-8762



PARAFON FORTE DSC

chlorzoxazone tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:49349-766(NDC:50458-625)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name		Basis of Strength	Strength	
CHLORZO XAZONE (UNII: H0DE420U8G) (CHLORZO XAZONE - UNII:H0DE420U8G)		CHLORZO XAZONE	500 mg	
Inactive Ingredients				
Ingredient Name		Strength		
cellulose, microcrystalline (UNII: OP1R32D61U)				
FD&C Blue No. 1 (UNII: H3R47K3TBD)				
docusate sodium (UNII: F05Q2T2JA0)				
lactose (UNII: J2B2A4N98G)				
magnesium stearate (UNII: 70097M6I30)				
sodium benzoate (UNII: OJ245FE5EU)				
STARCH, CORN (UNII: O8232NY3SJ)				
D&C Yellow No. 10 (UNII: 35SW5USQ3G)				
sodium starch glycolate type A potato (UNII: 5856J3G2A2)				
Product Characteristics				
Color	green	Score	2 pieces	
Shape	OVAL (TABLET)	Size	17mm	
Flavor		Imprint Code	PARAFON;FORTE;DSC;MCNEIL	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:49349-766-20	100 in 1 BOTTLE		
2	NDC:49349-766-16	50 in 1 VIAL		
3	NDC:49349-766-52	25 in 1 VIAL		
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA011529	11/28/2012		

Labeler - REMEDYREPACK INC. (829572556)

Revised: 11/2012

REMEDYREPACK INC.